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Table 2
Group Outcomes.
Outcomes African American (31) All Others (114) P-value
Median R¼ Median R¼
Days to ANC 28 1- 51 23 15- 60 0.31
Days to PLT Engraft 45 25-81 42 14- 105 0.93
Days to Chimerism 28 19- 97 29 13- 100 0.67
N[ % N[ %
Alive, Died 17, 14 54.8, 45.2 67, 47 58.8, 41.2 0.69
Relapse 1 of 31 4.8 16 of 64 21.6 0.11
aGVHD 11 35.5 55 48.2 0.23
cGVHD 2 6.4 6 5.3 0.68
ANC Engraft 20 64.5 82 71.9 0.51
PLT Engraft 17 54.8 79 69.3 0.14
Chimerism >95% 15 48.4 79 69.3 0.031
TRM 12 38.7 20 17.5 0.012
Graph 1: K-M Survival.
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(58%) are survivors. EFS > 1, 3 & 5 yr was 50%, 41% & 37%
respectively, OS was 60%, 48% & 43%. 34 pts (23%) are event
free for > 10 yr. Median follow up was 2.6 yr (1.2 - 16.4 yr).
Grade II- IV acute GVHD was seen in 66 pts (46%), chronic
GVHD in 8 (6%).
Conclusion: Children of African American ethnicity had
statistically signiﬁcant increased Transplant Related Mortal-
ity and showed poor chimerism compared to other groups.
There was no other statistical signiﬁcance between the two
groups with respect to age, diagnosis, HLA match, cell dose,
conditioning, survival, relapse, engraftment or GVHD. Also,
there was no difference in transplant outcomes of the other
individual ethnic groups.363
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Med/Pathology and Medicine, Mayo Clinic, Rochester, MNBackground: Haploinsufﬁciency of GATA2 results in familial
immunodeﬁciency and MDS/ AML. We present our experi-
ence with allogeneic stem cell transplant (HCT) for a family
with germline GATA2 mutations.
Methods: After due IRB approval, the myeloid neoplasms
data base at the Mayo Clinic, was queried for patients with
germline GATA2 mutations. A single family with 9 affected
members was identiﬁed. Clinical and laboratory data were
retrospectively abstracted.
Results: All family members had a c1339A>C, pS447R
germline GATA2 mutation (ﬁgure one). Unlike most other
disease causing GATA2 mutations this mutation occurred in
the non-zinc ﬁnger domain. All 9 affected members have
developed MDS/AML, with 3 having successfully undergone
allo-HCT.
The proband presented with AML-MRC and +8. He had
extensive HPV papillomas and a family history of MDS. He
received standard induction chemotherapy and developed
profound marrow aplasia and absidia sinusitis. He under-
went a reduced intensity conditioning 9/10 HLA-DQ MUD
allo HCT. The transplant was complicated by CMV reac-
tivation and acute grade 1 GI GVHD. His day 100 bone
marrow biopsy has shown 100% donor chimerisms with no
residual disease.
Patient No.2 was diagnosed to have MDS-RCMD. She
underwent a myeloablative 10/10 HLA MUD transplant. She
developed acute grade 1 Skin GVHD. Day 30 testing
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residual disease and 100 % donor chimerism.
Patient No.3 presented with refractory cytopenia with
marrow dysgranulopoiesis and dysmegakaryopoiesis
(Childhood MDS). She underwent a 9/10 HLA-DQ MUD
transplant. Post-transplant course was complicated by C
difﬁcile infection and acute grade 1 skin GVHD. At day 30 she
had 100 % donor chimerism.
Conclusion: Germline GATA2 mutations are associated with
a high frequency of MDS/AML. We describe a family with a
non-zinc ﬁnger GATA2 mutation causing MDS/AML, pro-
found B/NK deﬁciency and viral warts and describe the
successful role for allo-HCT in this setting.364
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ABO incompatibility among patients (pts) undergoing allo-
geneic stem cell transplant (ASCT) is associated with delayed
engraftment and post-transplant pure red cell aplasia
(PT-PRCA).Age D Gender
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43 AML M–>F 10/10MUD A+/O+ Flu/Bu PBSCT Skin 2 256 PL
Rit
60 AML M–>F 10/10MUD A+/O+ Flu/Bu PBSCT No 1024 Rit
38 AML M->M 9/10MUD A+/O+ Flu TBI PBSCT No 512 No
44 AML M–>F 10/10MRD AB+/O+ Cy/TBI PBSCT No 64 Rit
Da
63 AML F–>M 10/10MRD A+/O+ Flu/Bu PBSCT No > 2048 Rit
Da
57 AML M->M 10/10MUD A+/O+ Flu/Mel PBSCT Skin 1 1024 Da
Rit
PL
68 AML M->M 10/10MUD B+/O+ Flu/Mel PBSCT Skin 1 1024 No
51 ALL M–>F 10/10MUD A+/O+ Cy/TBI PBSCT No 1024 Rit
Da
63 ALL M–>F 10/10MUD A+/O+ Cy/TBI BMSCT Skin 1 UK Da
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Cy/TBI PBSCT No Neg PL
41 MDS M->M 10/10MUD AB+/O+ Cy/Bu PBSCT No 256 PL
33 MDS M->M 10/10MUD A+/O+ Pent/TBI PBSCT GI 1 Neg DaAfter due IRB approval we retrospectively analyzed the
prevalence and outcome of PT-PRCA among pts undergoing
ASCT at Mayo Clinic, Rochester between 1/1/2000 and 9/
30/2013. Out of 886 ASCT done during the period, we
identiﬁed 53(6%) pts with major ABO and 24 (3%) pts with
bi-directional ABO incompatibility. Twelve patients (1%)
developed PT-PRCA; 11 had major ABO incompatibility
while one had a bidirectional mismatch. All pts received
red cell depleted stem cells and there were no cases of
acute hemolysis. Six pts underwent reduced intensity
conditioning.
Median time to diagnosis of PT-PRCA was 42 days (23-
67), with reticulocytopenia and renewed transfusion
dependance. Pts were initially managed with immuno-
suppression taper and EPO supplementation. Refractory
cases were treated with plasmapheresis (4), rituximab (6)
and DLI (1). One pt relapsed and 2 pts died (both sepsis)
prior to resolution of PT-PRCA. After excluding these
pts median time to resolution of PT-PRCA was 113 days
(13-429).
PT-PRCA is not an uncommon complication of major ABO
incompatible ASCT. However it is relatively less common in
patients with bi-directional incompatibility. PT-PRCA results
in renewed transfusion dependance. Immunosuppression
taper and/or immunomodulation can serve as effective
treatment strategies.(In
dition
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